What are the opening hours?

Monday 10am - 5am Tuesday 10am - 5am Thursday 10am - 5am Friday 10am - 5am

MitoGENE Technologies

Home
India
Chennai
MitoGENE Technologies

Global medicine supplier | FDA/EMA-approved therapies via Named Patient Program | Generics & APIs for advanced treatments worldwide.

16/02/2026

Not all breast cancer medicines are immediately available in India.
Delays and uncertainty can add stress during treatment.

MitoGENE helps patients access required medicines legally and safely through the CDSCO Named Patient Program, in coordination with their treating oncologist.

👉 Know more about the process:
https://mitogene.org/accessing-datroway-in-india-for-advanced-breast-cancer-through-the-named-patient-program/

13/02/2026

DATROWAY not available in India?
Patients can access it legally through approved pathways.

MitoGENE provides guidance for safe and compliant access.
👉 Learn more at MitoGENE
https://mitogene.org/accessing-datroway-in-india-for-advanced-breast-cancer-through-the-named-patient-program/

11/02/2026

Accessing Libtayo in India involves careful medical validation and regulated delivery.

Read our detailed blog:
https://mitogene.org/facilitating-libtayo-access-for-pd-l1-positive-nsclc-in-india/

For access guidance, connect with Mitogene.

09/02/2026

Looking for a regulated pathway to access Libtayo in India?

Explore how MitoGENE supports patients and clinicians through a transparent and compliant process.
🔗 Read the case study:
https://mitogene.org/facilitating-libtayo-access-for-pd-l1-positive-nsclc-in-india/

06/02/2026

Libtayo access for advanced lung cancer patients in India can be supported through the CDSCO Named Patient Program.
MitoGene helps simplify the process with compliant and coordinated support.
👉 Learn how MitoGene can help:
https://mitogene.org/facilitating-libtayo-access-for-pd-l1-positive-nsclc-in-india/

04/02/2026

Eligible patients may access IMDELLTRA in India through the CDSCO Named Patient Program.

MitoGENE facilitates regulatory approvals, import, and delivery, ensuring compliant access and continuity of treatment.

Read the full guide 👉 https://mitogene.org/accessing-imdelltra-for-advanced-lung-cancer-through-indias-named-patient-program/

Contact MitoGENE for access support

02/02/2026

When a medicine is not available in India,
patients can still access it legally through special approval pathways.

With the right documentation and compliance,
the treatment is imported specifically for the patient.

MitoGENE guides patients and families through this process
with clarity and transparency.

Learn more:
👉 https://mitogene.org/accessing-imdelltra-for-advanced-lung-cancer-through-indias-named-patient-program/

29/01/2026

Some advanced lung cancer therapies may be accessed in India through structured regulatory pathways, even if they are not commercially available.

IMDELLTRA access is possible via the CDSCO Named Patient Program, with proper medical guidance and approvals. MitoGENE helps simplify this process for patients and healthcare providers.

Contact MitoGENE to access global medicines.
👉 Learn more:
https://mitogene.org/accessing-imdelltra-for-advanced-lung-cancer-through-indias-named-patient-program/

27/01/2026

Accessing global lung cancer medicines in India often involves complex regulatory steps.

MitoGENE helps enable access to advanced lung cancer treatments through the CDSCO Named Patient Program, supporting patients and healthcare providers with a clear and compliant process.

Learn more about how access to LUMAKRAS is enabled in India by visiting our blog.
👉 https://mitogene.org/enabling-access-to-lumakras-in-india-2/

22/01/2026

Access to LUMAKRAS (sotorasib) in India requires medical confirmation, regulatory approvals, and compliant import.

This visual outlines the key steps involved, from diagnosis to patient delivery, under proper medical supervision.

Learn how MitoGENE supports patients and families at every stage with clarity and compliance.
Read the full blog here:
👉 https://mitogene.org/enabling-access-to-lumakras-in-india-2/

20/01/2026

When a critical treatment is not available in India, the right pathway matters.
Learn how LUMAKRAS can be accessed legally through the Named Patient Program with proper guidance.

Read the detailed case study here:
https://mitogene.org/enabling-access-to-lumakras-in-india-2/

14/01/2026

Wishing you a Happy and Prosperous Pongal
May this festive season bring good health, peace, happiness, and new beginnings to you and your family.

Address

No:7, Plot:47/1, Selvaraj Nagar, Extn – 2, Urapakkam West
Chennai
603211

Opening Hours

Monday	10am - 5am
Tuesday	10am - 5am
Thursday	10am - 5am
Friday	10am - 5am

Website

http://mitogene.org/

Alerts

Be the first to know and let us send you an email when MitoGENE Technologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic in Chennai?